[Adverse effects of atazanavir].
Atazanavir is a drug that inhibits HIV protease. It has many of the characteristics of other protease inhibitors and also some advantages over these, such as the single dose of once per day, low capsule load, less gastrointestinal problems and a very friendly metabolic profile, including carbohydrate metabolism. Secondary high plasma bilirubin and jaundice are its main adverse effect which only on rare occasions requires stopping the drug. Other adverse effects, such as nephrolithiasis or ECG changes are extremely rare.
Palacios
R
R
Servicio de Medicina Interna, Hospital Virgen de la Victoria, Málaga, España.
González
M
M
Ruiz
J
J
Santos
Jesús
J
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D050260:Carbohydrate Metabolism / Q000187:drug effects; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D005947:Glucose / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D006946:Hyperinsulinism / Q000139:chemically induced; D007333:Insulin Resistance; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D052878:Urolithiasis / Q000139:chemically induced
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D005947:Glucose